The global mining sector is currently undergoing a transformative period, with gold-copper project exploration and development taking center stage. As of November 12, 2025, robust commodity prices, escalating geopolitical complexities, and an intensified focus on Environmental, Social, and Governance (ESG) principles are driving unprecedented activity. This dual demand for both
Regulatory Approvals For U.S. Steel Deal; BHP-Anglo American Deal Falls Through; U.S. GoldMining Sustainability Highlights And More: Thursday's Top Mining Stories
U.S. Steel accused Cleveland-Cliffs of sabotaging a deal, but Cliffs presents evidence countering the claims and criticizes U.S. Steel's mismanagement. ArcelorMittal is testing a carbon capture unit, U.S. GoldMining prepares for field season, and Southern Copper's Tia Maria mine is expected to break ground.
Renowned economist and gold advocate Peter Schiff used the drastic plunge in Peloton Interactive Inc (NASDAQ:PTON) stock to illustrate his theory on the mispricing of gold mining stocks.
Top Stories for March 8, 2024: 1. Cleveland-Cliffs Inc. (NYSE: CLF) is increasing spot market base prices for all carbon hot-rolled, cold-rolled and coated-steel products.
Top Stories for Jan. 19, 2024: 1. The boron and lithium company 5E Advanced Materials, Inc. (NASDAQ: FEAM) announced that it selected Fluor Corporation as its engineering, procurement and construction services provider.
In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New York Stock Exchange on Thursday, with shares opening at $42,
U.S. stocks traded slightly lower this morning, with the Dow Jones dropping around 40 points on Monday. Following the market opening Monday, the Dow traded down 0.12% to 33,635.06 while the NASDAQ fell 0.35% to 12,191.99. The S&P 500, also fell, dropping, 0.11% to 4,131.81.
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) gained 118% to $3.64 in pre-market trading after declining around 5% on Friday. ZyVersa Therapeutics recently posted a wider FY loss.
